Month: August 2021

06:00 London, 08:00 Helsinki, 20 August 2021 – Afarak Group Plc (“Afarak” or “the Company”) (LSE: AFRK, NASDAQ: AFAGR) FINANCIAL INTERIM RELEASE H1 2021 Afarak Group has restated its figures for H1 2020 due to the loss of control and the end of the consolidation of Afarak Mogale (Pty) Ltd. Afarak Group reclassified Afarak Mogale (Pty) Ltd’s previously reported income statement figures as discontinued operations. There is no change to the previously reported balance sheet figures.    H1/21 H1/20Restated 2020Revenue EUR million 37.3 35.5 59.8EBITDA EUR million -0.9 -0.3 -4.1EBIT EUR million 0.9 -1.7 -28.2Earnings before taxes EUR million -0.5 -4.1 -32.4Profit from continuing operations EUR million -0.9 -4.6 -27.6Profit from discontinuing operations EUR million 0.0 -11.5 6.1Profit EUR...

20 August 2021, Antwerp, Belgium: VGP NV (‘VGP’ or ‘the Group’), a European provider of high-quality logistics and semi-industrial real estate, announces the details for the audio webcast to review financial results for half-year ended 30 June 2021:Tuesday, 31 August 2021 at 10.30 a.m. (CET) Webcast link:https://event.webcasts.com/starthere.jsp?ei=1490414&tp_key=4b56f881dc Click on the link above to attend the presentation from your laptop, tablet or mobile device. Audio will stream through your selected devicePlease join the event audio webcast 5-10 minutes prior to the start time. The financial results are scheduled to be released at approximately 7:00 a.m. (CET) on the date noted above, and presentation slides will be made available on www.vgpparks.eu/en/investors/publications/ under Financial & Operating Results. CONTACT...

SAN DIEGO, Aug. 19, 2021 (GLOBE NEWSWIRE) — Progenity, Inc. (“Progenity”) (Nasdaq: PROG), an innovative biotechnology company, today announced the pricing of its previously announced underwritten public offering of 40,000,000 shares of its common stock and warrants to purchase up to 40,000,000 shares of its common stock. Each share of common stock is being sold together with one warrant to purchase one share of common stock at a combined public offering price of $1.00 per share of common stock and accompanying warrant, less underwriting discounts and commissions. The warrants have an exercise price of $1.00 per share, are exercisable immediately, and will expire five years following the date of issuance. Progenity expects to receive gross proceeds from the underwritten public offering of approximately $40 million, before deducting...

New York, NY, Aug. 19, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — AdvanceTC Ltd (NSX:A88)(OTCQB:ATCLF) (‘AdvanceTC’ or the ‘Company’), finalized its global distribution appointments to support continued growth and a commitment to future customers. The Company announced the appointment of four Regional Marketing Arms in its strategy to expand the distribution of its new satellite devices to the global market. AdvanceTC has historically been able to identify an isolated market, innovate and successfully launch a unique product whilst protecting its patent by using local manufacturing and assembly strategies. In 2012, AdvanceTC was the world’s first company to successfully launch a mobile communications device. The Magic W3 is a 4.8″ Windows®7 full OS touchscreen microcomputer with voice call functionality. The Magic W3...

Roxadustat is the first orally administered hypoxia-inducible factor (HIF) prolyl hydroxylase (PH) inhibitor available for adult patients with anemia associated with chronic kidney disease in Europe TOKYO, Aug. 19, 2021 (GLOBE NEWSWIRE) — Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique Conterno, “FibroGen”) today announced that the European Commission (EC) has approved EVRENZO™ (roxadustat) for the treatment of adult patients with symptomatic anemia associated with chronic kidney disease (CKD). “We are very pleased EVRENZO has been approved as the first oral HIF-PH inhibitor to treat adult patients with symptomatic anemia associated with CKD in the European Union,” said Steven Benner, M.D., M.H.S., President of Development,...

Highlights:Flowr has completed a strategic review process resulting in annualized SG&A savings of approximately $3.3 million, sale of non-core assets with aggregate proceeds of over $7 million, and a reduction of long-term debt by $7.5 million. In Canada, Flowr continues to focus on the premium and ultra-premium dry flower market. Flowr has received a sensory license from Health Canada allowing for the Company to continue to better understand consumer demands. Flowr has initiated its first export of medical cannabis to Israel opening a key distribution channel. In Europe, Holigen, a wholly-owned subsidiary of Flowr, has entered into the largest known bulk medical cannabis sale agreement in Portugal. Holigen to be the exclusive cultivation and retail partner for Cookies in Portugal with a view to bringing Cookies cannabis and...

NOT FOR DISTRIBUTION TO THE UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES RIMOUSKI, Quebec, Aug. 19, 2021 (GLOBE NEWSWIRE) — Puma Exploration Inc., PUMA-TSXV, (the “Company” or “Puma”) has closed the fully subscribed hard cash units offering for an amount of $1,600,000. The company issued five million units at the price of 32 cents per unit. Each unit comprises one common share and one common share purchase warrant. Each warrant gives its holder the right to purchase one common share at a price of 50 cents per share until August 19, 2023. Crescat Portfolio Management LLC (for itself and/or for accounts managed by Crescat Portfolio Management LLC (collectively, “Crescat”)), has participated as expected in the offering by making a strategic investment of $960,000, representing 60% of the financing. Two...

Q2 Recurring Revenues from Royalties and Interest of $ 1,692,000;YTD $3,302,000 — YoY growth of 48.3% TORONTO, Aug. 19, 2021 (GLOBE NEWSWIRE) — Flow Capital Corp. (TSXV: FW) (“Flow Capital”) announces its unaudited financial and operating results for the quarter ended June 30, 2021 (“Q2 2021”). Financial references are in Canadian dollars unless otherwise specified. Q2 2021 Performance HighlightsFree Cash Flow (FCF) of $4,493,358 in Q1 2021 compared to $42,140 in Q2 2020. Year-to-date (YTD) FCF of $4,898,550. Total revenue under IFRS of $4,922,505 in Q2 2021; a YoY growth of 168.3%. YTD revenue of $7,263,075; a year-over-year (YoY) growth of 148.1%. Net income of $3,065,893 in Q2 2021, compared to $27,897 in Q2 2020. YTD net income of $4,373,849. EBITDA of $4,105,927 in Q2 2021; an 8X growth over $525,094 in Q2 2020. YTD...